Biotech Values

[krenjp]

"1) They say the drug extended survival by x, but no mention what the comparison was against, or how they came up with it."


The PR says the drug "extended median survival by 6.7 months or 29 weeks after ALL other treatments were exhausted"

The "All treatments" would be 5-fluorouracil or capecitabine, irinotecan, and oxaliplatin, as well as other combinations of treatment" (Avastin etc)

The PR then says "7 had received four previous lines of treatment before entering the trial."

So it seems the data they announce refers to this sub-group of 7 and not their whole sample, a big NoNoNoNo.

isnt it Dew?